...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>AIDS Research and Human Retroviruses >Prevalence of Drug-Drug Interactions upon Addition of Simeprevir- or Sofosbuvir-Containing Treatment to Medication Profiles of Patients with HIV and Hepatitis C Coinfection
【24h】

Prevalence of Drug-Drug Interactions upon Addition of Simeprevir- or Sofosbuvir-Containing Treatment to Medication Profiles of Patients with HIV and Hepatitis C Coinfection

机译：在艾滋病毒和丙型肝炎合并感染患者的药物档案中加用含Simeprevir或Sofosbuvir的治疗后药物相互作用的发生率

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The objectives were to (1) compare the frequency of contraindicated drug-drug interactions (XDDI) when simeprevir (SIM)- and sofosbuvir (SOF)-containing regimens are theoretically added to a patient's medication profile; (2) identify which hepatitis C (HCV) regimen is associated with the lowest frequency of XDDIs within different types of antiretroviral treatment (ART) regimens; and (3) determine the risk factors for XDDIs with each regimen. A cross-sectional study was performed among adult HIV/HCV-coinfected patients. Demographics, comorbidities, and medication lists were collected from medical records. Medication lists were entered into Lexi-Interact drug interaction software and XDDI before/after the addition of SIM- and SOF-containing therapy was documented. Classification and regression tree (CART) analyses identified breakpoints in continuous variables. Before the addition of any HCV therapy, XDDIs were present in 20% of the 335 included patients. After the addition of SIM-containing therapy, the frequency of XDDIs significantly increased to 88.4% (p<0.001). After adding SOF-containing therapy, the prevalence of XDDIs increased to 24.5% (p<0.001). The prevalence of XDDIs was significantly lower for SOF-containing HCV therapy within various types of ART regimens. Use of >= 7 non-HIV medications (CART breakpoint) was the only variable to predict XDDIs before the addition of any HCV therapy. Similarly, this was the only variable to predict XDDIs after the addition of SOF-containing therapy (PR: 4.80; 95% CI: 2.57-8.96, p<0.001). Variables independently associated with XDDIs after the addition of SIM-containing therapy were NNRTI regimen (prevalence ratio, PR: 1.62; 95% confidence interval, CI: 1.38-1.91, p<0.001), PI regimen (PR: 1.64; 95% CI: 1.40-1.93, p<0.001), and >= 7 non-HIV medications (PR: 1.06; 95% CI: 1.00-1.14, p=0.09). The addition of SOF-containing therapy was associated with a lower prevalence of XDDI than SIM-containing therapy.
机译：目的是（1）比较理论上将含simeprevir（SIM）和sofosbuvir（SOF）的治疗方案中禁忌药物-药物相互作用（XDDI）的频率; （2）确定哪种丙型肝炎（HCV）方案与不同类型的抗逆转录病毒治疗（ART）方案中XDDI的最低发生率相关; （3）确定每种方案的XDDI危险因素。在成人HIV / HCV合并感染患者中进行了横断面研究。人口统计学，合并症和药物清单是从医疗记录中收集的。在记录包含SIM和SOF的治疗之前/之后，将药物清单输入Lexi-Interact药物相互作用软件和XDDI。分类和回归树（CART）分析连续变量中确定的断点。在添加任何HCV治疗之前，包括335名患者中的20％存在XDDI。添加含SIM的疗法后，XDDI的频率显着增加至88.4％（p <0.001）。加入含SOF的治疗后，XDDI的患病率上升至24.5％（p <0.001）。在各种类型的ART方案中，含SOF的HCV疗法的XDDI患病率显着降低。在添加任何HCV治疗之前，使用> = 7种非HIV药物（CART断点）是预测XDDI的唯一变量。同样，这是添加含SOF的疗法后预测XDDI的唯一变量（PR：4.80; 95％CI：2.57-8.96，p <0.001）。添加含SIM的疗法后，与XDDI独立相关的变量为NNRTI方案（患病率，PR：1.62; 95％置信区间，CI：1.38-1.91，p <0.001），PI方案（PR：1.64; 95％CI ：1.40-1.93，p <0.001），以及> = 7种非HIV药物（PR：1.06; 95％CI：1.00-1.14，p = 0.09）。与含SIM的疗法相比，含SOF的疗法与XDDI的患病率较低相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号